Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamiparib Maintenance in Platinum-sensitive Recurrent Ovarian Cancer
NCT03519230Phase 3Active, not recruiting
- Sponsor
- BeiGene
- Start
- May 2018
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pamiparib in ovarian cancer, sponsored by BeiGene. Started May 2018; status: active, not recruiting.
02
Drugs
pamiparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03519230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03519230.